Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17208794 | 0.96 | CA12 (0.65) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL29102400 | 0.92 | CA12 (0.56) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL18544334 | 0.89 | CA12 (0.55) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL30884514 | 0.85 | CA12 (0.60) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL5122634 | 0.85 | ALDH1A1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18569791 | 0.85 | CA12 (0.60) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL15392142 | 0.85 | CA12 (0.63) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL8705236 | 0.84 | CA12 (0.53) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL21601467 | 0.84 | CA12 (0.69) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL13726564 | 0.84 | CA12 (0.69) | CA12CA1CA2CA9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2026-04-16 | — | — | US | disclosed |
| EP-4637734-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARy AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025038781-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024134227-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARY AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2024-06-27 | — | — | WO | disclosed |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2021-12-07 | — | — | US | disclosed |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2021-12-07 | — | — | US | disclosed |
| CN-107567445-B | 2-phenyl-3H-imidazo [4,5-B ] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity | 坎塞拉有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130071936-A1 | FRET-BASED ZINC(II) ION INDICATOR | The Florida State University Research Foundation, Inc. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071936-A1 | FRET-BASED ZINC(II) ION INDICATOR | The Florida State University Research Foundation, Inc. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012000945-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | WO | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1813611-A1 | 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7015345-B2 | Propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1484316-A1 | NOVEL PROPIONIC ACID DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040072690-A1 | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA1 2560/4885CA2 4459/4885 |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | CA12 4529/4885CA1 4669/4885CA2 1533/4885 |
| US-20040072690-A1 | Novel propionic acid derivatives | PNLIP, LIPC, GPR119 | CA12 2779/4885CA1 2835/4885CA2 753/4885 |
| US-20130071936-A1 | FRET-BASED ZINC(II) ION INDICATOR | TFAM, MCU, TFB2M | CA12 1416/4885CA1 893/4885CA2 446/4885 |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | SLC5A1, SLC5A2, UGGT1 | CA12 2055/4885CA1 3165/4885CA2 944/4885 |
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | PPARG, FABP1, PPARA | CA12 3672/4885CA1 4134/4885CA2 3968/4885 |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA1 2560/4885CA2 4459/4885 |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA1 2560/4885CA2 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.